GLOBAL MED TECHNOLOGIES INC
Form 3
April 01, 2010

(Print or Type Responses)

1. Name and Address of Reporting Person:

| A HAEMONETICS CORP |  |  |
| :---: | :---: | :---: |
| (Last) | (First) | (Middle) |
| 400 WOOD ROAD, Â |  |  |
| (Street) |  |  |
| BRAINTREE, Â MAÂ 02184 |  |  |
| (City) | (State) | (Zip) |

1.Title of Security
(Instr. 4)
2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol Statement (Month/Day/Year) 03/25/2010

GLOBAL MED TECHNOLOGIES INC [GLOB]
4. Relationship of Reporting 5. If Amendment, Date Original Person(s) to Issuer Filed(Month/Day/Year)
(Check all applicable)

| $\quad$Director <br> Officer | X_1 Other <br> (give title below) |
| :--- | :--- |
| (specify below) |  |

6. Individual or Joint/Group

Filing(Check Applicable Line) Person filed by One Reporting Person
_X_Form filed by More than One
Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
2. Amount of Securities
3.

Beneficially Owned (Instr. 4)

Ownership Ownership
Form: (Instr. 5)
Direct (D)
or Indirect
(I)
(Instr. 5)
Common Stock
I See Footnote (1)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

> Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)


Shares
$\hat{\mathrm{A}} \underline{(2)(3)} \quad \hat{\mathrm{A}} \underline{(2)(3)} \quad \begin{aligned} & \text { Common } \\ & \text { Stock }\end{aligned} 5,500,000 \quad \$ 0.72 \underline{(4)} \quad$ I $\quad$ See Footnote (1)

Series A Convertible Preferred Stock

## A

## Reporting Owners

Reporting Owner Name / Address

HAEMONETICS CORP
400 WOOD ROAD
BRAINTREE, Â MAÂ 02184
Atlas Acquisition Corp.
C/O HAEMONETICS CORPORATION $\hat{\text { A }}$ A X A $\hat{\mathrm{A}}$ 400 WOOD ROAD
BRAINTREE,Â MAÂ 02184

## Signatures

HAEMONETICS CORPORATION /s/ Christopher J. Lindop, its Chief Financial Officer
${ }_{-}^{* *}$ Signature of Reporting Person
04/01/2010
Date
ATLAS ACQUISITION CORP. /s/ Christopher J. Lindop, its President
04/01/2010
$\stackrel{* *}{\sim}$ Signature of Reporting Person
Date

## Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. $78 f f(a)$. The reported securities are owned indirectly by Haemonetics Corporation ("Haemonetics") and directly by Atlas Acquisition Corp.
(1) ("Atlas"), a wholly-owned subsidiary of Haemonetics. The reported securities were acquired by Atlas in connection with the cash tender offer to purchase all outstanding shares of convertible preferred stock and Common Stock of the Issuer commenced by Atlas on February 19, 2010.
(2) Subject to the "blocker" provisions described in footnote 3, the convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date.
The convertible preferred stock is subject to "blocker" provisions prohibiting the holder from converting the preferred stock to the extent
(3) that such conversion would result in the holder being deemed the beneficial owner of more than $9.99 \%$ of the issued and outstanding shares of the Common Stock.
(4)

Subject to the "blocker" provisions described in footnote 3, the shares of convertible preferred stock are convertible at a rate of 1-to-1,388.89 into the number of shares of Common Stock shown in column 3.
$\hat{A}$

## Remarks:

This $\hat{A}$ report $\hat{A}$ is $\hat{A}$ filed $\hat{A}$ jointly $\hat{A}$ by $\hat{A}$ Haemonetics $\hat{A}$ Corporation $\hat{A}$ and $\hat{A}$ Atlas $\hat{A}$ Acquisition $\hat{A}$ Corp.
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

